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Abstract
Introduction Rapamycin, an inhibitor of the serine/threonine
kinase target of rapamycin, induces G1 arrest and/or apoptosis.
Although rapamycin and its analogues are attractive candidates
for cancer therapy, their sensitivities with respect to growth
inhibition differ markedly among various cancer cells. Using
human breast carcinoma cell line MCF-7 as an experimental
model system, we examined the growth-inhibitory effects of
combinations of various agents and rapamycin to find the agent
that most potently enhances the growth-inhibitory effect of
rapamycin.
Method We evaluated the growth-inhibitory effect of rapamycin
plus various agents, including cotylenin A (a novel inducer of
differentiation of myeloid leukaemia cells) to MCF-7 cells, using
either MTT assay or trypan blue dye exclusion test. The cell cycle
was analyzed using propidium iodide-stained nuclei.
Expressions of several genes in MCF-7 cells with rapamycin
plus cotylenin A were studied using cDNA microarray analysis
and RT-PCR. The in vitro results of MCF-7 cells treated with
rapamycin plus cotylenin A were further confirmed in vivo in a
mouse xenograft model.
Results We found that the sensitivity of rapamycin to MCF-7
cells was markedly affected by cotylenin A. This treatment
induced growth arrest of the cells at the G1 phase, rather than
apoptosis, and induced senescence-associated β-
galactosidase activity. We examined the gene expression
profiles associated with exposure to rapamycin and cotylenin A
using cDNA microarrays. We found that expressions of cyclin
G2, transforming growth factor-β-induced 68 kDa protein,
BCL2-interacting killer, and growth factor receptor-bound 7
were markedly induced in MCF-7 cells treated with rapamycin
plus cotylenin A. Furthermore, combined treatment with
rapamycin and cotylenin A significantly inhibited the growth of
MCF-7 cells as xenografts, without apparent adverse effects.
Conclusion Rapamycin and cotylenin A cooperatively induced
growth arrest in breast carcinoma MCF-7 cells in vitro, and
treatment with rapamycin and cotylenin A combined more
strongly inhibited the growth of MCF-7 cells as xenografts in
vivo  than treatment with rapamycin or cotylenin A alone,
suggesting that this combination may have therapeutic value in
treating breast cancer. We also identified several genes that
were markedly modulated in MCF-7 cells treated with rapamycin
plus cotylenin A.
Introduction
Breast cancer is the most frequent cancer disease among
women in the Western world, accounting for almost 30% of all
cancers among women. Although there have been advances
in the areas of early detection and treatment, the incidence of
this disease has increased and mortality rates are almost unal-
tered [1]. Because oestrogen exposure is considered to be a
major factor in the development of breast cancer and because
most breast cancers maintain their hormonal dependency, the
nonsteroidal antioestrogen tamoxifen has been the leading
BIK = BCL2-interacting killer; CI = combination index; CN-A = cotylenin A; EGR = early growth response; FKBP12 = FK506-binding protein; GAPDH 
= glyceraldehyde-3-phosphate dehydrogenase; GRB = growth factor receptor-bound; mTOR = mammalian target of rapamycin; MTT = 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS = phosphate-buffered saline; RT-PCR = reverse transcription polymerase chain reaction; 
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drug in the treatment of advanced breast cancer for more than
30 years. However, the development of resistance to antihor-
monal therapy is a major problem in the treatment of breast
cancer patients [2,3]. Therefore, the development of a new
strategy for suppressing the growth of breast cancer cells is
required.
Rapamycin and its analogues are promising new drugs that
use alternative mechanisms to inhibit the growth of breast can-
cer cells [4,5]. Rapamycin, a macrolide fungicide, was first iso-
lated from Streptomyces hygroscopicus in the early 1970s
and was initially developed clinically for its immunosuppres-
sant properties. Subsequently, rapamycin became of signifi-
cant interest as a potential antitumour drug.
Rapamycin first binds the 12-kDa immunophilin FK506-bind-
ing protein (FKBP12), and this complex then inhibits mamma-
lian target of rapamycin (mTOR) – a serine/threonine kinase.
mTOR is recognized as a central controller of eukaryotic cell
growth and proliferation, in that it senses nutritional status and
mitogens in mammalian cells and allows for the progression
from G1 to S phase, although it may not be the only target of
rapamycin. Clinically, rapamycin analogues with improved sta-
bility and pharmacological properties have been well tolerated
by patients in phase I trials, and these agents have exhibited a
promising antitumour effect in several types of refractory
tumour, including breast cancer [6,7]. However, the sensitivi-
ties of rapamycin with respect to growth inhibition differ mark-
edly among various cancer cells, and only a minority of patients
in each tumour lineage appear to respond to rapamycin ana-
logues [5]. To improve therapeutic efficacy against a broad
range of human tumour cells, we must develop new and potent
derivatives of rapamycin. Alternatively, application of synergis-
tic combinations of rapamycin and some agents may lead to a
potent therapy for some types of solid tumours.
Differentiation-inducing agents can alter the phenotype of can-
cer cells, including their sensitivity to anticancer drugs. We
previously reported that treatment with hemin, an inducer of
erythroid differentiation, greatly increased the sensitivity of
human myeloid leukaemia K562 cells to 1-β-d-arabinofurano-
sylcytosine, and that erythroid differentiation factor (activin A)
enhanced the sensitivity of multidrug-resistant leukaemia cells
to vincristine, actinomycin D and doxorubicin [8,9]. In the
present investigation, we examined the synergistic effects of
various differentiation-inducing agents and rapamycin on the
growth of mammary carcinoma cells to identify the most potent
and clinically applicable drugs. The most effective agent was
cotylenin A (CN-A), which has a novel fusicoccane-diterpene
glycoside with a complex sugar moiety. It was originally iso-
lated as a plant growth regulator, and has been shown to
affect several physiological processes in higher plants and to
have differentiation-inducing activity in several human and
murine myeloid cell lines [10-14]. In leukaemia cells that were
freshly isolated from patients with acute myelogenous leukae-
mia, CN-A has also been found to affect the differentiation of
cells in primary culture [15]. This differentiation-inducing activ-
ity was more potent than those of all-trans retinoic acid and
1α,25-dihydroxyvitamin D3.
Apart from the potent differentiation-inducing activity in vitro,
the administration of CN-A also significantly prolonged the
survival of mice with severe combined immunodeficiency that
had been inoculated with cells of human promyelocytic leukae-
mia cell line NB4 [16]. No appreciable adverse effects were
observed with this treatment, suggesting that CN-A may be
useful in treating leukaemia and other malignancies.
Recently, we found that CN-A and interferon-α synergistically
inhibited growth and induced apoptosis in several human non-
small-cell lung carcinoma cell lines. Furthermore, this com-
bined treatment markedly inhibited the growth of human lung
cancer cells as xenografts [17]. In the present study, we found
that treatment with the combination of rapamycin and CN-A
synergistically inhibited the proliferation of human breast can-
cer MCF-7 cells in vitro, and that this combined treatment also
induced growth arrest of the cells at G1 phase, rather than
inducing apoptosis. We also identified several genes that
were markedly modulated in MCF-7 cells treated with rapamy-
cin plus CN-A. Furthermore, we examined the therapeutic
effects on xenografts of human breast carcinoma cells.
Materials and methods
Materials
Rapamycin was purchased from Sigma Chemical (St. Louis,
MO, USA). CN-A was purified from a stock ethyl acetate
extract obtained from the culture filtrate of Cladosporium fun-
gus sp. 501-7W by flash chromatography on silica gel with
more than 99% purity [10,11]. A stock solution of CN-A was
prepared in absolute ethanol at 20 mg/ml.
Cells and cell culture
Human breast carcinoma cell lines (MCF-7, T-47D and MDA-
MB-231) and human promyeloblastic leukaemia cell line NB-4
were cultured in RPMI 1640 supplemented with 10% foetal
bovine serum at 37°C in a humidified atmosphere of 5% car-
bon dioxide in air.
Assay of cell growth
The cells were seeded at 1–3 × 104/ml in a 24-well multidish.
After culture with or without the test compounds for the indi-
cated times, viable cells were examined using either the trypan
blue dye exclusion test or a modified MTT (3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide) assay. In the MTT
assay, 100 µl MTT solution (1 mg/ml in PBS) was added to
each well and cells were incubated for 4 hours. The cells were
then centrifuged at 1000 g for 10 min and the precipitates
were dissolved in 1 ml dimethyl sulphoxide; their absorption at
560 nm was determined. Assay of the cumulative cell number
was determined as described elsewhere [17].Available online http://breast-cancer-research.com/content/7/6/R1097
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Analysis of the effects of combinations of drugs
Isobologram analysis was used to determine the effects of
combinations of drugs on MCF-7 cells. Dose-dependent
effects were determined for each compound and for one com-
pound with fixed concentrations of another. The interaction of
two compounds was quantified by determining the combina-
tion index (CI), in accordance with the following classic isobo-
logram [18]:
CI = (D)1/(Dx)1 + (D)2/(Dx)2
Where Dx is the dose of one drug alone required to produce
an effect, and (D)1 and (D)2 are the doses of compounds 1 and
2, respectively, in combination that produce the same effect.
From this analysis, the combined effects of the two drugs can
be summarized as follows: CI = 1 indicates summation (addi-
tive and zero interaction); CI < 1 indicates synergism; and CI
> 1 indicates antagonism.
Cell cycle analysis
The cell cycle was analyzed using propidium iodide-stained
nuclei. Samples of 2 × 106 cells were harvested at the time
points indicated, washed in ice-cold PBS, fixed by the addition
of 100% ethanol and left for 30 min on ice. The cell pellet was
washed and suspended in 200 µl 1.12% sodium citrate con-
taining RNase A (250 µg/ml) for 30 min at room temperature.
Thereafter, the cells were stained with 50 µg/ml propidium
iodide in the presence of 1.12% sodium citrate and analyzed
in a fluorescence-activated cell sorter.
Assay of E-cadherin and senescence markers
The expression of E-cadherin was detected by immunocyto-
chemistry. Cells were fixed in 4% paraformaldehyde in PBS
and permeabilized in acetone at 4°C. Slides were pretreated
in PBS containing 0.2% Tween-20, blocked with 5% normal
goat serum and 0.2% Tween-20 in PBS, and incubated with
rabbit polyclonal antibody to E-cadherin (Santa Cruz, CA,
USA). Antibody–antigen complexes were visualized using
DAKO ENVISION/AP kit (DakoCytomation Japan, Kyoto,
Japan). Senescence-associated β-galactosidase (SA-βGal)
activity was determined as described by Dimri and coworkers
[19]. SA-βGal activity was monitored visually by scoring blue
precipitate in the cytoplasm.
cDNA microarray analysis
Total RNA was isolated from MCF-7 cells treated with or with-
out compound for 12 hours using Isogen (Nippon Gene,
Toyama, Japan) [20]. Poly(A)+RNA was reverse transcribed
with the concomitant incorporation of Cy3- and Cy5-labelled
nucleotides. The labelled probes were hybridized with a cDNA
microarray, representing about 16,000 different human genes
(TaKaRa Bio Inc., Tokyo, Japan), and their fluorescent intensi-
ties were scanned according to the protocol standardized by
TaKaRa Bio Inc. The genes were screened by analyzing the
difference in expression profiles between two genes.
Gene expression analysis by RT-PCR
Total RNA was extracted using Isogen (Nippon Gene), in
accordance with the manufacturer's instructions. Total RNA (1
µg) from tumour cells was converted to first-strand cDNA
primed with random nonamer in a reaction volume of 20 µl
using an RNA PCR kit (TaKaRa Bio), and 4 µl of this reaction
was used as a template in the PCR. The oligonucleotides used
in PCR amplification are summarized in Table 1. PCR con-
sisted of 25 cycles for transforming growth factor-β-induced
68 kDa protein (TGFBI), BCL2-interacting killer (BIK) and
early growth response (EGR)3; 22 cycles for cyclin G2; 27
cycles for growth factor receptor-bound (GRB)7; and 17
cycles for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH); with denaturing at 94°C for 30 s, annealing at 60°C
for 30 s and extension at 72°C for 30 s. The linearity of the
quantitation of RT-PCR products was determined using [α-
32P]dCTP and various amounts of total RNA, as described in
the literature [20]. Under these conditions, the amounts of
PCR products increased linearly up to 0.4 µg total RNA.
Table 1
Oligonucleotides used in PCR amplification
Sense strand Antisense strand
TGFBI 5'-TGTGTGCTGTGCAGAAGGTT-3' 5'-ATATGGTAGCGGAGGGCATT-3'
BIK 5'-CTCCAGAGACATCTTGATGG-3' 5'-TGGGATCTCCAGAACCTCATT-3'
Cyclin G2 5'-AGCACTTGGCAGGTCATGAA-3' 5'-CAACTATTCTAGCAGCCAGC-3'
GRB7 5'-TCTGCCTGAGGAGGTAAAGA-3' 5'-GGAGCTCTTGAACAGTTCGT-3'
EGR3 5'-CTACTTGGGAAAGTTCGCCT-3' 5'-GAATGCCTTGATGGTCTCCA-3'
GAPDH 5'-GGTCGGAGTCAACGGATTTG-3' 5'-ATGAGCCCCAGCCTTCTCCAT-3'
BIK, BCL2-interacting killer; EGR, early growth response; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GRB, growth factor receptor-
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Transplantation of MCF-7 cells into nude mice and 
treatment
Female athymic nude mice with a BALB/c genetic background
were supplied by CLEA Japan (Tokyo, Japan). They were
housed under specific pathogen-free conditions. The in vivo
experiments were performed in accordance with the guide-
lines of our institute (Guide for Animal Experimentation,
Saitama Cancer Center, Saitama, Japan). One week before
MCF-7 cell inoculation, mice each received 2 µg of 17β-
oestradiol valerate (Sigma), dissolved in 0.2 ml of sesame oil,
by subcutaneous injection. Oestrogen injections were
repeated every week to sustain tumour growth. Mice were
inoculated subcutaneously with 2 × 107 MCF-7 cells. By day
21 after inoculation, all of the tumours were about the same
size. The animals were randomly distributed into four groups of
20 mice each. A stock solution of CN-A for administration was
prepared in dimethyl sulphoxide at 100 mg/ml, and rapamycin
was dissolved in ethanol at 1 mg/ml. Mice were given a daily
intraperitoneal injection of 0.1 ml PBS, including 100 ng
rapamycin, and/or subcutaneous injections every other day of
0.2 ml of PBS, including 100 µg CN-A, at a site distant from
the tumours. Tumour size was measured with vernier calipers
every other day. Statistical analysis was performed using Stu-
dent's t-test.
Results
Combined effects of rapamycin and cotylenin A on the 
growth of MCF-7 cells
We examined the synergistic effects of various agents, includ-
ing differentiation inducers and rapamycin, on growth inhibi-
tion of cells of breast cancer cell line MCF-7. Sensitivity to
anticancer agents such as 5-fluorouracil, cisplatin and doxoru-
bicin was barely affected by rapamycin. All-trans retinoic acid
(a typical differentiation inducer), but not vitamin D3, affected
the growth of MCF-7 cells, and the growth-inhibitory effect of
rapamycin was significantly enhanced by all-trans  retinoic
acid, although a high concentration of retinoic acid was
required (data not shown).
Among the differentiation-inducing agents tested, the sensitiv-
ity of MCF-7 cells to rapamycin was most affected by CN-A, a
novel inducer of the differentiation of myeloid leukaemia [12-
Figure 1
Synergistic effects of rapamycin and CN-A on the growth of MCF-7 cells Synergistic effects of rapamycin and CN-A on the growth of MCF-7 cells. (a) Cells (3 × 104 cells/ml) were cultured with various concentrations of 
rapamycin and CN-A for 5 days. After culture, cells were stained with May–Grunwald–Giemsa. (b) Cells (3 × 104 cells/ml) were cultured without 
(white circle) or with (white triangle) 0.5 ng/ml rapamycin, 10 µg/ml CN-A (white square), or 0.5 ng/ml rapamycin plus 10 µg/ml CN-A (black circle) 
for the indicated number of days. The values are expressed as mean ± standard deviation of four determinations. (c) Cells were cultured without 
(white circle) or with (white triangle) 0.5 ng/ml rapamycin, 10 µg/ml CN-A (white square), or 0.5 ng/ml rapamycin plus 10 µg/ml CN-A (black circle) 
for the indicated number of days. The culture medium was replaced by fresh medium at least once every 5 days. The cell density was kept at 1–8 × 
104 cells/ml. The values are expressed as mean ± SD of four separate experiments. CN-A, cotylenin A.
Figure 2
Classic isobologram at IC50: rapamycin plus CN-A in MCF-7 cells Classic isobologram at IC50: rapamycin plus CN-A in MCF-7 cells. Iso-
boles for the combination of rapamycin with CN-A that were isoeffec-
tive (IC50) for inhibition of proliferation of MCF-7 cells. The dashed line 
indicates the zero interaction of the isobole. Cells (3 × 104 cells/ml) 
were treated with rapamycin and CN-A for 5 days. Values are the 
means of three separate experiments. CN-A, cotylenin A; IC50, the con-
centration of the drug required for 50 % inhibition of cell growth.Available online http://breast-cancer-research.com/content/7/6/R1097
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16]. Figure 1 shows the synergistic effects of rapamycin and
CN-A on the growth of MCF-7 cells. Figure 1a shows the
May–Gruenwald–Giemsa staining pattern of MCF-7 cells
after 5-days of treatment with various concentrations of both
rapamycin and CN-A. Figure 1b shows the time course of the
combined effects of rapamycin and CN-A on the growth of
MCF-7 cells. The growth of MCF-7 cells was inhibited moder-
ately by rapamycin (0.5 ng/ml) or CN-A (10 µg/ml) alone, but
growth was still seen at least until 5 days, whereas the cell
number did not change after 1 day of treatment with the com-
bination of rapamycin and CN-A. Figure 2 shows isoboles for
the combination of rapamycin with CN-A that were isoeffective
(IC50 : the concentration of the drug required for 50 % inhibi-
tion of cell growth) for inhibition of proliferation of MCF-7 cells.
These isoboles indicate that the combination of these drugs
had synergistic effects.
We also examined the long-term effects of combined treat-
ment with rapamycin and CN-A on the proliferation of MCF-7
cells (Fig. 1c). The growth rate of rapamycin-treated cells was
almost the same as that of control cells after 5 days. Cell
growth was significantly inhibited by CN-A alone after 5 days,
but the cell number was still increased even at day 23. On the
other hand, cell growth was greatly inhibited by combined
treatment with rapamycin and CN-A, and the cell number at
day 23 was almost the same as that at day 5 (Fig. 1c).
Similar growth-inhibitory effects of rapamycin and CN-A were
observed in two other human breast cancer cell lines (oestro-
gen receptor-positive T-47D cells and oestrogen receptor-
negative MDA-MB-231 cells; Fig. 3a,b). Furthermore, these
combined effects of rapamycin and CN-A were also observed
in several different tumour cell lines such as human promyelo-
cytic leukaemia NB-4 cells (Fig. 3c) and human non-small-cell
lung carcinoma A549 and Lu99 cells (data not shown). These
findings indicate that the growth-inhibitory effects of rapamy-
cin plus CN-A were not restricted to MCF-7 cells.
To establish the most effective treatment procedure using
rapamycin and CN-A on MCF-7 cells, we examined the effects
of various different treatments on MCF-7 cells. MCF-7 cells
were seeded at 1 × 104 cells/ml and the number of viable cells
was determined by MTT assay after 7 days. Simultaneous
treatment with rapamycin (0.5 ng/ml) and CN-A (2.5 µg/ml) for
7 days was most effective at inhibiting cell proliferation (96%
inhibition). Furthermore, we found that the timing of the addi-
tion of CN-A was critical to the inhibitory affect on the cell
number. When CN-A was added at day 2, the combined
growth-inhibitory effect was markedly decreased at 7 days
(29% inhibition). On the other hand, when rapamycin was
added at day 1 or day 2, the combined growth-inhibitory
effects were almost completely conserved at 7 days (95% or
90% inhibition, respectively). We also found that an initial
short exposure to CN-A was enough to exert the combined
effect. When cells were treated with CN-A for only 1 day from
day 0 to day 1 in the presence of rapamycin, and then cultured
only in the presence of rapamycin from day 2 to day 7, the
combined growth-inhibitory effects were still almost com-
pletely preserved at 7 days (90% inhibition). These findings
indicate that simultaneous treatment with rapamycin and CN-
A is the most effective procedure for inhibiting the cell growth
of MCF-7 cells and that initial 1-day treatment with CN-A and
continuous treatment with rapamycin has almost the same
growth-inhibitory effects as simultaneous treatment with
rapamycin and CN-A.
Induction of G1 arrest in MCF-7 cells treated with 
rapamycin plus cotylenin A
To better understand the combined effects of rapamycin and
CN-A on cell growth, we exposed MCF-7 cells to 0.5 ng/ml
Figure 3
Combined effect of rapamycin and CN-A on the growth of human cancer cells Combined effect of rapamycin and CN-A on the growth of human cancer cells. (a) human breast cancer T-47D cells (3 × 104 cells/ml) were treated 
with CN-A in the absence (black triangle) or the presence (black circle) of 0.5 ng/ml rapamycin for 5 days. (b) human breast cancer MBA-MB-231 
(3 × 104 cells/ml) cells were treated with CN-A in the absence (black triangle) or the presence (black circle) of 15 ng/ml rapamycin for 5 days. (c) 
human promyelocytic leukaemia NB-4 cells (3 × 104 cells/ml) were treated with CN-A in the absence (black triangle) or the presence (black circle) 
of 0.5 ng/ml rapamycin for 5 days. Values are expressed as mean ± standard deviation for three separate experiments. CN-A, cotylenin A.Breast Cancer Research    Vol 7 No 6    Kasukabe et al.
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rapamycin and 10 µg/ml CN-A, and then measured the
changes in the cell cycle distribution after 6 days. This
concentration of rapamycin or CN-A alone did not affect the
cell cycle in our study, whereas rapamycin with CN-A induced
growth arrest of cells at the G1 phase (Fig. 4). The induction of
apoptosis (cells in sub-G1 phase) was not observed in cells
with the combined treatment.
Induction of phenotypic changes in MCF-7 cells treated 
with rapamycin and cotylenin A
Because treatment with rapamycin and CN-A induced G1
arrest but not apoptosis, these treatments may induce
phenotypic changes in MCF-7 cells. Changes in several differ-
entiation-associated phenotypes were examined, but the
expression of casein or mucin was not significantly induced by
the combined treatment. Intracellular accumulation of lipid
droplets was also not observed (data not shown). However,
when we cultured MCF-7 cells for 7 days, CN-A greatly
enhanced the expression of E-cadherin, and the expression
was significantly enhanced by rapamycin (Fig. 5). We also
found that CN-A alone or CN-A plus rapamycin could induce
activity of SA-βGal (Fig. 5), which is one of the markers of
senescence of epithelial cells [21]. These findings suggest
that this combined treatment with rapamycin and CN-A
induced growth arrest of cells at the G1 phase and may induce
phenotypic changes toward cell senescence but not
apoptosis.
Effects of the combined treatment with rapamycin plus 
cotylenin A on expression of p53, p21Cip1, p27Kip1 and 
cyclins
To elucidate the mechanism underlying the G1 arrest mediated
by rapamycin plus CN-A, we then examined the expression of
several genes, using RT-PCR, that are important for cell cycle
regulation. We first examined the expression of p53 in MCF-7
cells (Fig. 6a). Unexpectedly, the expression of p53 was not
affected when MCF-7 cells were treated with 1 ng/ml
rapamycin alone, 2.5–10 µg/ml CN-A alone, or 1 ng/ml
rapamycin plus 2.5 µg/ml CN-A for 24 hours. HL60 cells were
used as a negative control for p53 expression.
Because the p21Cip1 and p27Kip1 Cdk inhibitors play important
roles in cell cycle regulation, especially in response to external
agents, we then examined the levels of expression of these
two genes (Fig. 6a). The expression levels of p21Cip1, which is
a target gene of p53, and p27Kip1 were also not induced by
these treatments. Cyclin D1 plays an important role in G1
Figure 4
Induction of G1 arrest in MCF-7 cells treated with rapamycin plus CN-A Induction of G1 arrest in MCF-7 cells treated with rapamycin plus CN-A. 
Cells were cultured (a) without or (b) with 10 µg/ml CN-A, (c) 0.5 ng/
ml rapamycin, or (d) 0.5 ng/ml rapamycin plus 10 µg/ml CN-A for 6 
days, and DNA histograms were then analyzed. CN-A, cotylenin A.
Figure 5
Induction of phenotypic changes in MCF-7 cells treated with CN-A and  rapamycin Induction of phenotypic changes in MCF-7 cells treated with CN-A and 
rapamycin. Upper row: E-cadherin. Cells were cultured in the presence 
(right) or absence (left) of 10 µg/ml CN-A plus 0.5 ng/ml of rapamycin 
for 7 days. Lower row: SA-βGal activity. Cells were cultured in the pres-
ence (right) or absence (left) of 10 µg/ml CN-A plus 0.5 ng/ml rapamy-
cin for 7 days. CN-A, cotylenin A; Rapa, rapamycin; SA-βGal, 
senescence-associated β-galactosidase.Available online http://breast-cancer-research.com/content/7/6/R1097
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phase cell cycle progression, and previous work
demonstrated that rapamycin decreased expression of cyclin
D1 and c-myc [22]. When MCF-7 cells were treated with 0.5
ng/ml rapamycin and 10 µg/ml CN-A for 12 hours, expression
of cyclin D1 or c-myc was not inhibited by the combined treat-
ments (Fig. 6b). On the other hand, expression of cyclin E1 was
slightly inhibited by the combined treatments (Fig. 6b).
cDNA microarray analysis of MCF-7 cells treated with 
rapamycin, cotylenin A, and rapamycin + cotylenin A
Because we could not detect major changes in the expression
of cell cycle regulating genes using RT-PCR (Fig. 6), we con-
ducted a cDNA microarray analysis of MCF-7 cells and
screened genes that were upregulated or downregulated by
rapamycin plus CN-A. MCF-7 cells were cultured with 0.5 ng/
ml rapamycin or 10 µg/ml CN-A, or both combined for 12
hours and total RNA was used in the microarray analysis.
When MCF-7 cells were cultured with the same treatments for
5-day, the levels of growth inhibition induced by rapamycin,
CN-A, and rapamycin plus CN-A were 31%, 40% and 90%,
respectively.
Genes with a treatment:control ratio greater than 2 were con-
sidered to be significantly upregulated, and those with a ratio
below 0.5 were considered to be significantly downregulated.
Many more genes were upregulated and downregulated upon
exposure to rapamycin plus CN-A than with rapamycin or CN-
A alone. Whereas individually rapamycin and CN-A upregu-
lated 61 and 46 genes and downregulated 33 and 26 genes,
respectively, combined treatment with rapamycin and CN-A
upregulated 225 genes and downregulated 186 genes. Fur-
thermore, 41 genes were upregulated more than threefold in
MCF-7 cells treated with rapamycin plus CN-A, although only
one gene and eight genes were upregulated more than three-
fold in rapamycin-treated and CN-A-treated MCF-7 cells,
respectively. These findings suggest that rapamycin and CN-
A can also induce synergistic effects on the induction of gene
expression. Table 2 shows 25 genes that were highly upregu-
lated (>3.4-fold) by rapamycin plus CN-A. Among these 25
upregulated genes, nine and 17 were upregulated (>2-fold) in
rapamycin-treated and CN-A-treated cells, respectively.
TGFBI [23], BIK [24], cyclin G2 [25,26] and GRB7 [27] were
upregulated by more than 5.8-fold in MCF-7 cells treated with
rapamycin plus CN-A.
Table 3 shows 25 genes that were highly downregulated
(gene expression ratio <0.38) by both rapamycin and CN-A.
Thirteen genes were downregulated by less than one-third in
cells treated with the combined treatment. In cells treated with
CN-A alone or the combined treatment, the expression of
EGR3 [28] was decreased to about one-fifth of that in control
MCF-7 cells. Table 4 shows the effects of rapamycin plus CN-
A on the expressions of several cell cycle regulatory genes. As
mentioned above, the expression of cyclin G2 (gene expres-
sion ratio 6.08) was markedly induced, whereas the expres-
sions of cyclin E1  (gene expression ratio 0.44) and E2F
transcription factor 3 (gene expression ratio 0.42) were mod-
erately downregulated in the rapamycin plus CN-A treated
cells.
Time course of highly upregulated gene expression by 
rapamycin plus cotylenin A
To confirm the results of the cDNA microarrray analysis, the
expressions of highly upregulated genes were examined by
RT-PCR. Figure 7a shows the time course patterns of gene
expression of TGFBI, BIK, cyclin G2 and GRB7. Figure 7b
shows graphs of the relative levels of mRNA after normaliza-
tion to GAPDH mRNA levels. These findings confirm the data
from the cDNA microarray analysis. In these genes, the
expression of cyclin G2 was increased fourfold at 3 hours after
combined treatment and further increased with time (>8 fold
at 24 hours). The expression of GRB7 was also induced by
more than threefold at 3 hours after combined treatment, and
the expression levels remained almost constant, at least until
24 hours. Expression of the TGFBI and BIK genes were mark-
edly induced by the combined treatment after 12 hours. These
genes were quickly and highly upregulated after the addition
of rapamycin plus CN-A, and so they may play a crucial role in
growth inhibition in human breast carcinoma cells treated with
rapamycin plus CN-A.
Effects of rapamycin and cotylenin A on the in vivo 
growth of MCF-7 cells as xenografts
The in vitro studies described above suggested that com-
bined treatment with rapamycin and CN-A should be more
therapeutically effective than treatment with rapamycin or CN-
A alone. At day 20 after inoculation of human breast carcinoma
Figure 6
Effects of rapamycin and CN-A on the expressions of p53, p21Cip1,  p27Kip1 and cyclins Effects of rapamycin and CN-A on the expressions of p53, p21Cip1, 
p27Kip1 and cyclins. Expression of mRNAs was examined by RT-PCR 
analysis. (a) MCF-7 cells were cultured with 2.5–10 µg/ml CN-A or 1 
ng/ml rapamycin, or both combined for 24 hours. (b) MCF-7 cells were 
cultured with 0.5 ng/ml rapamycin or 10 µg/ml CN-A, or both combined 
for 12 hours. The levels of GAPDH expression are shown to demon-
strate that equal amounts of RNA were used for RT-PCR. CN-A, coty-
lenin A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Breast Cancer Research    Vol 7 No 6    Kasukabe et al.
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MCF-7 cells the tumour volume (mean ± standard deviation)
was 119 ± 59 mm3, and treatments were then started. We
administered 0.1 µg rapamycin/mouse every day and 100 µg
CN-A/mouse every other day. These treatments had no appre-
ciable adverse effects on the mice. The combined treatment
significantly inhibited the growth of MCF-7 cells as xenografts
(Fig. 8). Injections of solvent alone did not inhibit the growth of
MCF-7 cells in vivo (Fig. 8). At day 18 after treatment, the
mean tumour volumes in untreated, rapamycin treated, CN-A
treated, and rapamycin + CN-A treated nude mice were 1336
± 332 mm3, 659 ± 181 mm3, 848 ± 237 mm3 and 245 ± 62
mm3, respectively. Although rapamycin and CN-A each signif-
icantly retarded tumour growth (P < 0.05), combined treat-
ment induced the arrest of tumour growth. The treatment was
continued for 18 days and then stopped, with follow up on day
48. All of the untreated, rapamycin treated and CN-A treated
mice had a greater tumour burden at day 48. On the other
hand, all mice treated with rapamycin plus CN-A still had a
much smaller tumour burden (data not shown), suggesting
that the therapeutic effects were still maintained after treat-
ment was terminated. These findings indicate that the
combination of rapamycin and CN-A is more therapeutically
effective than treatment with rapamycin or CN-A alone, and
the combined treatment had a significant antitumour effect (P
< 0.001).
Table 2
Upregulated genes in MCF-7 cells after exposure to rapamycin plus CN-A for 12 hours
Gene expression ratio
GenBank number Gene name Rapamycin + CN-A Rapamycin CN-A
NM_000358.1 Transforming growth factor-β-induced 68 kDa (TGFBI) 8.16 1.74 5.2
NM_001038.1 Sodium channel, nonvoltage-gated 1α(SCNN1A) 6.99 1.49 4.26
NM_002281.2 Keratin, hair, basic-1 (KRTHB1) 6.96 1.27 12.8a
NM_001197.3 BCL2-interacting killer (apoptosis-inducing; BIK) 6.76 2.37 3.59
NM_004354.1 Cyclin G2 (CCNG2) 6.08 3.07 3.22
NM_005310.1 Growth factor receptor-bound protein 7 (GRB7) 5.81 2.48 2.61
NM_020898.1 KIAA1536 protein (KIAA1536) 5.42 2.78 1.8
NM_030777.2 Solute carrier family 2, member 10 (SLC2A10) 5.09 1.53 2.51
NM_005727.2 Tetraspan 1 (TSPAN-1) 4.61 1.54 1.76
NM_024709.1 Hypothetical protein FLJ14146 (FLJ14146) 4.55 1.8 2.53
NM_014376.1 Cytoplasmic FMR1 interacting protein 2 (CYFIP2) 4.21 2.43 1.66
NM_017644.1 Hypothetical protein FLJ20059 (FLJ20059) 4.09 1.51 1.2
NM_002166.1 Inhibitor of DNA binding 2 (ID2) 4.03 1.23 2.93
NM_006813.1 Proline rich 2 (PROL2) 3.87 2.8 1.9
NM_002885.1 RAP1, GTPase activating protein 1 (RAP1GA1) 3.81 1.56 2.51
NM_000755.2 Carnitine acetyltransferase (CRAT) 3.79 1.75 2.45
NM_031477.2 Hypothetical protein MGC10500 (MGC10500) 3.72 2.18 2.29
NM_012257.2 HMG-box containing protein 1 (HBP1) 3.7 1.67 1.55
NM_020169.2 Latexin protein (LXN) 3.68 2.49 2.40
NM_014417.2 BCL2 binding component 3 (BBC3) 3.55 1.82 2.18
NM_024642.2 GalNAc-T12 (GALNT12) 3.49 1.49 2.53
NM_016162.1 Inhibitor of growth family, member 4 (ING4) 3.47 1.98 1.73
NM_017673.2 Chromosome 1 open reading frame 26 (C1orf26) 3.45 1.44 2.93
NM_014353.2 RAB26, member RAS oncogene family (RAB26) 3.42 2.40 1.49
NM_005178.2 B-cell CLL/lymphoma 3 (BCL3) 3.39 1.05 3.31
aIncreased upper reliable levels. CN-A, cotylenin A.Available online http://breast-cancer-research.com/content/7/6/R1097
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Discussion
Rapamycin and its analogues are now in clinical trials as anti-
cancer agents that may potently inhibit tumour cell
proliferation [4-7]. We have reported that rapamycin or CN-A
alone could induce the differentiation of human myeloid leu-
kaemia cells [12-16]. We previously screened the antiprolifer-
ative effects of differentiation inducers in myeloid leukaemia
cells on several solid tumour cells. In this study, we found that
combined treatment with rapamycin and CN-A synergistically
inhibited the proliferation of human breast cancer MCF-7 cells
in vitro and had a marked antitumour effect on MCF-7 cells
grown in nude mice. The combined treatment induced growth
arrest of the cells at the G1 phase rather than apoptosis. Fur-
thermore, the combined treatment strongly enhanced the
expression of E-cadherin. CN-A and CN-A plus rapamycin was
able to induce SA-βGal activity, which is one of the markers of
senescence of epithelial cells [21]. These findings suggest
that the combined treatment may induce phenotypic changes
toward cell senescence but not apoptosis.
In the present study we showed that the proliferation of human
mammary carcinoma MCF-7 cells was synergistically inhibited
by treatment with the combination of rapamycin and CN-A.
Similar growth-inhibitory effects of rapamycin and CN-A were
observed in two other human breast cancer cell lines
(oestrogen receptor-positive T-47D cells and oestrogen
receptor-negative MDA-MB-231 cells; Fig. 3a,b). These
results suggest that the growth-inhibitory activity of rapamycin
and CN-A may be independent of the presence of oestrogen
receptor in tumour cells. Furthermore, similar growth-inhibitory
Table 3
Downregulated genes in MCF-7 cells after exposure to rapamycin plus CN-A for 12 hours
Gene expression ratio
GenBank number Gene name Rapamycin + CN-A Rapamycin CN-A
XM_097230.3 Similar to Cerebellin-like glycoprotein 1 (LOC147381) 0.15 0.93 0.22
NM_006417.2 Interferon-induced protein 44 (IFI44) 0.18 0.62 0.24
XM_095568.5 Hypothetical protein DKFZp762C1112 (DKFZp762C1112) 0.19 1.13 0.29
NM_006820.1 Chromosome 1 open reading frame 29 (C1orf29) 0.20 0.83 0.21
NM_004430.1 Early growth response 3 (EGR3) 0.21 0.53 0.19
NM_024563.1 Hypothetical protein FLJ14054 (FLJ14054) 0.22 0.52 0.45
NM_017816.1 Hypothetical protein FLJ20425 (LYAR) 0.28 0.44 0.45
NM_004934.2 Cadherin 18, type 2 (CDH18) 0.28 1.10 0.20
NM_152454.1 Hypothetical protein FLJ31461 (FLJ31461) 0.29 1.11 0.29
XM_084501.3 Hypothetical protein LOC143381 (LOC143381) 0.29 1.36 0.24
NM_004704.1 RNA, U3 small nucleolar interacting protein 2 (RNU3IP2) 0.30 0.61 0.65
NM_006993.1 Nucleophosmin/nucleoplasmin, 3 (NPM3) 0.32 0.48 0.47
NM_003504.2 CDC45 cell division cycle 45-like (S. cerevisiae) (CDC45L) 0.32 0.48 0.69
XM_059689.2 Similar to agCP15329 (LOC134111) 0.34 0.69 0.38
NM_015179.1 KIAA0690 protein (KIAA0690) 0.35 0.56 0.71
NM_014520.1 MYB binding protein (P160) 1a (MYBBP1A) 0.35 0.53 0.62
XM_300777.1 Similar to muscle protein (LOC348523) 0.35 0.70 0.69
NM_032509.1 RNA binding protein (LOC84549) 0.35 0.47 0.75
NM_014503.1 Downregulated in metastasis (DRIM) 0.36 0.48 0.56
NM_000269.1 Nonmetastatic cells 1, protein (NM23A) expressed in (NME1) 0.37 0.58 0.65
XM_050219.6 Synaptopodin 2 (SYNPO2) 0.37 0.93 0.57
XM_295865.1 LOC340895 (LOC340895) 0.37 1.34 0.33
NM_133263.1 PPAR gamma coactivator 1β(PERC) 0.37 0.62 0.74
NM_002220.1 Inositol 1,4,5-trisphosphate 3-kinase A (ITPKA) 0.37 0.60 0.62
NM_015068.1 Oaternally expressed 10 (PEG10) 0.38 0.77 0.43
CN-A, cotylenin A.Breast Cancer Research    Vol 7 No 6    Kasukabe et al.
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effects of rapamycin and CN-A were also observed in human
non-small-cell lung carcinoma A549 and Lu99 cells (data not
shown) and human promyelocytic leukaemia NB-4 cells (Fig.
3c), but not in human monocytic leukaemia THP-1 cells or
human ovary carcinoma OVCAR-5 cells. Rapamycin barely
inhibited the proliferation of THP-1 cells and OVCAR-5 cells,
although CN-A dose dependently inhibited the proliferation of
THP-1 cells and OVCAR-5 cells (data not shown). These
results indicate that the synergistic growth-inhibitory effects of
rapamycin plus CN-A are observed not only in MCF-7 cells but
also in other cancer cells, and suggest that moderate to low
sensitivity, but not insensitivity, to rapamycin is necessary to
exert the synergistic growth-inhibitory effects of rapamycin
plus CN-A in cancer cells.
Previous papers have demonstrated that rapamycin induces
the inhibition of cell proliferation and G1 arrest possibly due to
downregulation of the expressions of cyclin D1 and c-myc, and
upregulation of the expressions of p21Cip1 and p27Kip1 through
rapamycin-induced mTOR inhibition in various cancer cells,
including MCF-7 cells [5,6]. Furthermore, various agents such
as PM-3 (a benzo-γ-pyran derivative), flavopiridol, 2-(4-amino-
3-methylphenyl)-5-fluorobenzothiazole (5F-203; an anticancer
drug) and oncostatin M induced growth arrest of MCF-7 cells
and inhibited the expression of cyclin D1 and/or c-myc, or
upregulated the expression of p21Cip1 at the transcriptional
level [21,29-31]. These reports suggest that downregulation
of the expressions of cyclin D1 and c-myc, and up-regulation of
the expressions of p21Cip1 and p27Kip1 are important to growth
arrest of MCF-7 cells.
Table 4
Effects of rapamycin plus CN-A on cell cycle regulatory genes
Gene expression ratio
Gene name Rapamycin + CN-A Rapamycin CN-A
Cyclin A2 0.51 0.54 0.82
Cyclin B1 0.71 0.77 0.84
Cyclin B2 0.84 0.89 0.89
Cyclin D1 0.94 0.96 1
Cyclin D3 0.86 0.7 1.09
Cyclin E1 0.44 0.67 0.66
Cyclin E2 0.53 0.64 0.87
Cyclin G1 1.43 1.25 1.02
Cyclin G2 6.08 3.07 3.22
Cyclin-dependent kinase 2 (CDK2) 0.58 0.78 0.83
Cyclin-dependent kinase 4 (CDK4) 0.62 0.81 0.77
Cell division cycle 2 (CDC2) 0.62 0.7 0.85
P53 1.37 1.52 1.32
P21 (Cip1) 0.85 0.83 1.03
P27 (Kip1) 1.65 1.39 1.18
Retinoblastoma 1 (RB1) 1.08 1.09 1.04
Retinoblastoma-like 1 (p107) 0.53 0.67 0.87
Retinoblastoma-like 2 (p130) 1.96 2.18 1.07
E2F transcription factor 3 (E2F3) 0.42 0.86
E2F transcription factor 5, p130-binding (E2F5) 0.96 1.21 0.81
E2F transcription factor 6 (E2F6) 0.62 0.70 0.65
CN-A, cotylenin A.Available online http://breast-cancer-research.com/content/7/6/R1097
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In the present study, at the doses used, neither rapamycin nor
CN-A alone induced G1 arrest or significantly affected the
expressions of cyclin D, p21Cip1, p27Kip1 or c-myc. Further-
more, even when rapamycin in combination with CN-A
induced G1 arrest of MCF-7 cells, the expressions of these
genes were not significantly affected. These findings suggest
that other critical genes are important for the induction of
growth arrest of MCF-7 cells by rapamycin plus CN-A. Alter-
natively, the synergistic effects of rapamycin plus CN-A may
be exerted by an mTOR-independent pathway. However, this
possibility is extremely unlikely because the synergistic effects
of rapamycin and CN-A could be blocked by the presence of
FK506 on MCF-7 cells (data not shown). It is believed that
rapamycin and FK506, which have structural similarities,
compete for binding to FKBP12. However, only the complex
between rapamycin and FKBP12 is able to bind to mTOR,
thereby inhibiting mTOR's role in protein synthesis and the cell
cycle [4-7].
Among highly modulated genes induced by rapamycin plus
CN-A, we postulate that cyclin G2, TGFBI, BIK, GRB7 and
EGR3 may play important roles in the induction of the growth
inhibition of MCF-7 cells by rapamycin plus CN-A. Cyclin G2,
together with cyclin G1 and cyclin I, defines a novel cyclin fam-
ily expressed in terminally differentiated tissues. Cyclin G2
expression is upregulated as cells undergo cell cycle arrest or
apoptosis in response to inhibitory stimuli independent of p53
[25,26,32]. We found a marked induction (>6-fold) in cyclin
G2 in rapamycin plus CN-A treated MCF-7 cells (Table 2, Fig.
7). The expression of cyclin G2 was significantly upregulated
at 1 hour after combined treatment and then further upregu-
lated with time (>8-fold at 24 hours; Fig. 7). Frasor and cow-
orkers [33] reported that in oestrogen-treated MCF-7 cells,
the expression of cyclin G2 was quickly downregulated. Max-
well and coworkers [34] reported a microarray analysis after
treatment of MCF-7 cells with 5-fluorouracil, and found that 5-
fluorouracil upregulated the expression of cyclin G, although
they did not discriminate between cyclin G1 and cyclin G2.
These previous reports and our findings suggest that, in
human breast cancer MCF-7 cells, cyclin G2 may be a key neg-
ative regulator of cell cycle progression.
TGFBI is an extracellular matrix protein whose expression can
be induced by transforming growth factor-β [23]. Previous
reports [23,35,36] have suggested that TGFBI is involved in
cell growth, cell differentiation, cell adhesion and apoptosis,
Figure 7
Time courses of TGFBI, BIK, cyclin G2 and GRB7 mRNA expression in  MCF-7 cells Time courses of TGFBI, BIK, cyclin G2 and GRB7 mRNA expression in 
MCF-7 cells. (a) MCF-7 cells were treated without (lanes 1, 5, 9, 13 
and 17) or with 0.5 ng/ml rapamycin (lanes 2, 6, 10, 14 and 18), 10 µg/
ml CN-A (lanes 3, 7, 11, 15 and 19), or 0.5 ng/ml rapamycin plus 10 
µg/ml CN-A (lanes 4, 8, 12, 16 and 20) for 1, 3, 6, 12 and 24 hours. 
Expression of mRNAs was examined by RT-PCR analysis. (b) Graphs 
depict the relative levels of mRNA after normalization to GAPDH mRNA 
levels in Fig. 5a. Cells were treated with 0.5 ng/ml rapamycin (white tri-
angle) or 10 µg/ml CN-A (white square), or both combined (black cir-
cle). BIK, BCL2-interacting killer; CN-A, cotylenin A; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; GRB, growth factor 
receptor-bound; TGFBI, transforming growth factor-β-induced 68 kDa 
protein.
Figure 8
Effects of rapamycin and CN-A on the growth of MCF-7 cells as  xenografts Effects of rapamycin and CN-A on the growth of MCF-7 cells as 
xenografts. Mice were given a daily intraperitoneal injection of 100 ng 
rapamycin (black square, black circle) and/or subcutaneous injection of 
100 µg of CN-A (black triangle, black circle) every other day. Values are 
expressed as mean ± standard deviation of 20 mice. Black diamond, 
untreated mice; white circle, mice treated with solvent alone. CN-A, cot-
ylenin A; *, p < 0.05; **, p < 0.001.Breast Cancer Research    Vol 7 No 6    Kasukabe et al.
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and that it may act as a tumour suppressor. Rapamycin plus
CN-A strongly induced TGFBI expression in MCF-7 cells.
Because the expression of transforming growth factor-β3 was
upregulated 2.2-fold in these cells at 12 hours after treatment
with rapamycin plus CN-A (microarray data; data not shown),
it will be interesting to determine whether the marked induc-
tion of TGFBI expression is mediated by the induction of trans-
forming growth factor-β3 gene expression.
BIK is a BH3-only proapoptotic protein and forms heterodim-
ers with various antiapoptotic proteins, including Bcl-2 and
Bcl-XL [24]. BIK triggers apoptosis through a p53-independ-
ent pathway. Systemically administrated BIK inhibited the
growth of human breast cancer cells implanted in nude mice
and prolonged the life span of the treated animals [37].
Although we did not observe evidence of induction of apopto-
sis in combination-treated MCF-7 cells, upregulated BIK may
contribute to the suppression of growth in MCF-7 cells.
GRB7 is an adaptor molecule that mediates signal transduc-
tion from multiple cell surface receptors to various down-
stream signalling pathways. GRB7 and its related family
members GRB10 and GRB14 share a conserved molecular
architecture including Src homology 2 (SH2) and pleckstrin
homology (PH) domains. GRB7 has been implicated to be a
downstream mediator of integrin–FAK signal pathways in the
regulation of cell migration [27], whereas recent studies have
suggested that GRB10 and GRB14 play important roles in
cell proliferation [38,39]. In the present study, we found that
rapamycin plus CN-A specifically upregulated expression of
the GRB7 gene but not the expressions of other genes in this
family (Table 2, data not shown). Because the biological roles
and molecular mechanisms of this family of genes are still not
well understood, it is possible that the specific and early
upregulation of GRB7 gene expression may contribute to the
combined treatment-induced inhibition of the growth of MCF-
7 cells.
EGR3 is an immediate-early and zinc-finger transcription fac-
tor [28]. Oestradiol-treated MCF-7 cells exhibited rapid and
marked induction of EGR3 gene expression [33,40]. The
EGR3 gene is a critical transcription factor for Fas ligand
expression in MCF-7 cells as well as T cells [40,41]. Inoue and
coworkers [40] suggested that EGR3 plays an important role
in the oestrogen-dependent induction of the immune evasion
system in oestrogen receptor-positive breast cancer. The
present data showed that the expression of EGR3 was
markedly downregulated by CN-A alone or rapamycin plus
CN-A in MCF-7 cells. Thus, MCF-7 cells in which expression
of the EGR3 gene is downregulated might be more suscepti-
ble to immune surveillance in vivo.
We showed that rapamycin and CN-A cooperatively induced
growth arrest in breast carcinoma MCF-7 cells in vitro, and
that treatment with the combination of rapamycin and CN-A
more strongly inhibited the growth of MCF-7 cells as
xenografts in vivo than did treatment with rapamycin or CN-A
alone. The combined treatment also induced the arrest of
tumour growth (Fig. 8). Even when treatment was continued
for 18 days and then stopped, with follow up on day 48 all of
the mice treated with rapamycin plus CN-A still had a much
smaller tumour burden (data not shown). These results sug-
gest that the combination of rapamycin and CN-A also
induced growth arrest of the cells at the G1 phase in vivo and
then might induce cell senescence. This treatment has no
apparent effects on mice (with regard to body weight and
behaviour). Taken together, these findings suggest that treat-
ment with the combination of rapamycin and CN-A may be a
promising therapeutic strategy for human breast cancer,
although the mechanisms underlying the synergistic action of
this combined treatment require further investigation.
Conclusion
We found that rapamycin and CN-A, a novel inducer of the dif-
ferentiation of myeloid leukaemia cells, synergistically inhibited
the proliferation of mammary carcinoma MCF-7 cells. This
combined treatment induced growth arrest of the cells at the
G1 phase, rather than apoptosis, and induced activity of SA-
βGal, which is one of the markers of senescence of epithelial
cells. Although the expressions of p53, p21Cip1, p27Kip1 and
cyclin D1 mRNAs did not significantly change, we found that
expressions of several genes such as cyclin G2, TGFBI, BIK,
GRB7 and ERG3 were markedly modulated in MCF-7 cells
treated with rapamycin plus CN-A. Furthermore, the combined
treatment with rapamycin and CN-A significantly inhibited the
growth of MCF-7 cells as xenografts without apparent adverse
effects, suggesting this combination may have therapeutic
value in treating breast cancer.
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